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Abstract: Under healthy conditions, pancreatic β-cells produce and secrete the insulin hormone
in response to blood glucose levels. Under diabetic conditions, however, β-cells are compelled to
continuously secrete larger amounts of insulin to reduce blood glucose levels, and thereby, the β-cell
function is debilitated in the long run. In the diabetic state, expression levels of insulin gene
transcription factors and incretin receptors are downregulated, which we think is closely associated
with β-cell failure. These data also suggest that it would be better to use incretin-based drugs at
an early stage of diabetes when incretin receptor expression is preserved. Indeed, it was shown
that incretin-based drugs exerted more protective effects on β-cells at an early stage. Furthermore,
it was shown recently that endothelial cell dysfunction was also associated with pancreatic β-cell
dysfunction. After ablation of insulin signaling in endothelial cells, the β-cell function and mass
were substantially reduced, which was also accompanied by reduced expression of insulin gene
transcription factors and incretin receptors in β-cells. On the other hand, it has been drawing much
attention that incretin plays a protective role against the development of atherosclerosis. Many basic
and clinical data have underscored the importance of incretin in arteries. Furthermore, it was shown
recently that incretin receptor expression was downregulated in arteries under diabetic conditions,
which likely diminishes the protective effects of incretin against atherosclerosis. Furthermore, a series
of large-scale clinical trials (SPAED-A, SPIKE, LEADER, SUSTAIN-6, REWIND, PIONEER trials)
have shown that various incretin-related drugs have beneficial effects against atherosclerosis and
subsequent cardiovascular events. These data strengthen the hypothesis that incretin plays an
important role in the arteries of humans, as well as rodents.
Keywords: pancreatic β-cell dysfunction; atherosclerosis; incretin signaling; insulin signaling
1. Molecular Mechanism for Pancreatic β-Cell Dysfunction
1.1. MafA and PDX-1 Play a Crucial Role in Pancreatic β-Cells
Under healthy conditions, pancreatic β-cells function to produce and secrete the insulin hormone
in response to high glucose concentrations. Under diabetic conditions, however, β-cells are compelled to
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secrete larger amounts of insulin continuously in order to reduce blood glucose levels. Such succession
is some grueling work for β-cells themselves, and thereby, the β-cell function is debilitated in the
long run (so called “pancreatic β-cell glucose toxicity”) [1–3]. Chronic hyperglycemia reduces insulin
biosynthesis and secretion together with reduced expression of insulin gene transcription factors
such as MafA and PDX-1. In clinical practice, it is very important to alleviate such β-cell glucose
toxicity so that the aggravation of diabetes mellitus is forestalled. In addition, insulin signaling in
insulin target tissues (liver, skeletal muscle, and adipose tissue) is weakened by the burden of glucose
toxicity, leading to the development of insulin resistance. Such debilitation of the β-cell function and
development of insulin resistance lead to further aggravation of type 2 diabetes mellitus (Figure 1).
Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 2 of 13 
 
compelled to secrete larger amounts of insulin continuously in order to reduce blood glucose levels. 
Such succession is some grueling work for β-cells themselves, and thereby, the β-cell function is 
debilitated in the long run (so called “pancreatic β-cell glucose toxicity”) [1–3]. Chronic 
hyperglycemia reduces insulin biosynthesis and secretion together with reduced expression of 
insulin gene transcription factors such as MafA and PDX-1. In clinical practice, it is very important 
to alleviate such β-cell glucose toxicity so that the aggravation of diabetes mellitus is forestalled. In 
addition, insulin signaling in insulin target tissues (liver, skeletal muscle, and adipose tissue) is 
weakened by the burden of glucose toxicity, leading to the development of insulin resistance. Such 
debilitation of the β-cell function and development of insulin resistance lead to further aggravation 
of type 2 diabetes mellitus (Figure 1). 
 
Figure 1. Involvement of glucose toxicity in pancreatic β-cell dysfunction and insulin resistance. 
Under diabetic conditions, pancreatic β-cell function is gradually debilitated by the burden of glucose 
toxicity. In addition, insulin signaling in insulin target tissues (liver, skeletal muscle, and adipose 
tissue) is weakened by the burden of glucose toxicity, leading to the development of insulin resistance. 
Such debilitation of the β-cell function and development of insulin resistance bring about a vicious 
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MafA is a strong transcription factor for the insulin gene [4–19]. In MafA knockout mice, insulin 
biosynthesis and secretion are reduced, leading to diabetes mellitus, indicating the importance of 
MafA in β-cells [8]. The MafA expression level is markedly reduced in a diabetic state [11], but it is 
preserved after alleviation of glucose toxicity with some anti-diabetic agent [16–19]. Furthermore, we 
reported that in β-cell-specific and conditional (tamoxifen-induced) MafA overexpressing transgenic 
db/db mice, serum insulin levels were higher and blood glucose levels were lower compared to their 
littermates. In addition, the β-cell mass was preserved in MafA overexpressing db/db mice mainly 
due to the reduction of apoptotic cell death. We think that these findings clearly underscore the 
importance of MafA in β-cells and become unequivocal evidence that downregulation of MafA 
expression is associated with β-cell glucose toxicity (Figure 1).  
PDX-1, another important transcription factor for the insulin gene, plays a crucial role in 
pancreas development and β-cell differentiation and maintenance of mature β-cell function [20–31]. 
In PDX-1 knockout mice, pancreas formation is not observed at all [23]. In mature β-cells, PDX-1 
transactivates several genes including insulin, glucokinase, and glut2. However, the expression level 
of PDX-1 is reduced in a diabetic state [26,29], which we think is associated with β-cell failure 
Figure 1. Involvement of glucose toxicity in pancreatic β-cell dysfunction and insulin resistance.
Under diabetic conditions, pancreatic β-cell function is gradually debilitated by the burden of glucose
toxicity. In addition, insulin signaling in insulin target tissues (liver, skeletal muscle, and adipose
tissue) is weakened by the burden of glucose toxicity, leading to the development of insulin resistance.
Such debilitation of the β-cell function and development of insulin resistance bring about a vicious
cycle and finally lead to further aggravation of type 2 diabetes mellitus.
MafA is a strong transcription factor for the insulin gene [4–19]. In MafA knockout mice,
insulin bio ynthesis and secreti are reduced, leading to diabetes mellitus, indicating the importance
of MafA in β-cells [8]. The MafA expression level is markedly red ced in a diabetic state [11], but it
is preserved after alleviation of glucose toxicity with some anti-diabetic agent [16–19]. Furthermore,
we reported that inβ-cell-specifi and conditional (ta oxifen induced) MafA overexpressing transgenic
db/db mice, serum in ulin levels were higher and blood glucos levels were lowe compared to their
littermates. In add tion, the β-cell mass was preserved in MafA overexpressing db/db ice mainly due
o the reduction of apop otic cell death. We think that these findings cl arly underscore the importance
of MafA in β-cells and become un quivocal evidence t at downregulation of MafA expression is
ass ci ted with β-cell glucose toxicity (Figure 1).
PDX-1, nother important transcription factor for the insulin gene, plays a crucial role in pancreas
development and β-cell differen i tion and main enance of mature β-cell function [20–31]. In PDX-1
k ockout mice, pancre s formation is not observed at all [23]. In mature β-cells, PDX-1 ra sactivates
several ge es including insulin, glucokinase, and glut2. However, the expression level of PDX-1 is
redu ed in a diabetic state [26,29], which we think is associated with β-cell failure observ d in
diabetes. Ind ed, we recently reported that β-cell-specific and conditional (tamoxifen-induced) PDX-1
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overexpressing transgenic Akita mice showed lower blood glucose levels and lower HbA1C values
compared to their littermates, accompanied by increased insulin secretion after glucose loading [31].
Expression levels of MafA and glucokinase were preserved in PDX-1 overexpressing Akita mice.
We think that such new findings suggest that the downregulation of PDX-1 expression found in
diabetes undermines insulin biosynthesis and secretion which explains, at least in part, the mechanism
for β-cell glucose toxicity (Figure 1).
1.2. Incretin Signaling Plays an Important Role in Pancreatic β-Cells
In response to the ingestion of food, glucagon-like peptide-1 (GLP-1) and glucose-dependent
insulinotropic polypeptide (GIP) are released from the gastrointestinal tract both of which stimulate
insulin secretion. GLP-1 and GIP bind to the GLP-1 and GIP receptor in β-cells, respectively,
which increases intracellular cAMP levels. Increased cAMP levels lead to augmenting insulin secretion,
reducing β-cell apoptosis, and facilitating β-cell proliferation (Figure 2). Incretin-related drugs such as
glucagon-like peptide-1 receptor (GLP-1R) activators or dipeptidyl peptidase-IV (DPP-IV) inhibitors
are known to ameliorate glycemic control and reduce the progression of β-cell dysfunction in human
subjects, as well as rodent models [32–35]. Indeed, it was reported that the GLP-1 receptor activator
liraglutide preserved pancreatic β-cell function through the reduction of glucose toxicity, as well as
through its direct effect on β-cells [32,35]. The DPP-IV inhibitor suppresses the activity of DPP-IV,
which is a splitting enzyme of incretin and increases serum levels of GLP-1 and GIP. Both incretins
stimulate insulin secretion in a glucose-dependent manner and GLP-1 suppresses glucagon secretion.
Indeed, it has been reported that DPP-IV inhibitors preserve pancreatic β-cell function through the
reduction of glucose toxicity, as well as through the direct protective effect of incretin [33,34].
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Figure 2. Mechanism of action of incretin and incretin-based agents in pancreatic β-cells and reduced
expression of incretin receptor in β-cells in a diabetic state. Binding of incretin to incretin receptor in
β-cell membrane increases intracellular cAMP levels, which finally leads to augmentation of insulin
secretion from β-cells, reduction of β-cell apoptosis, and facilitation of β-cell proliferation. In a healthy
state, the incretin receptor is abundantly expressed in the β-cell membrane, but in a diabetic state,
the incretin receptor expression is substantially reduced.
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1.3. Incretin Receptor Expression in β-Cells Is Downregulated under Diabetic Conditions: Incretin-Based
Agents Exert More Protective Effects on β-Cells at an Early Stage of Diabetes rather than an Advanced Stage
It is well known that the incretin hormone action is significantly reduced in subjects with type
2 diabetes mellitus. Moreover, it has been reported that expression levels of incretin receptors are
decreased in a diabetic state, which is likely involved in the impaired incretin effects and the progression
of β-cell failure found in diabetes [16,36–38] (Figure 2). In addition, it has been suggested that the
decreased expression of transcription factor 7-like 2 (TCF7L2), which is a transcription factor of
incretin receptors and plays a crucial role in the maintenance of β-cell function, is involved in the
downregulation of the incretin receptor expression in β-cells found in diabetes [39–41].
It was reported that incretin-related drug liraglutide increased the β-cell function and mass at
an early stage of diabetes, but these effects were attenuated at an advanced stage [35]. Only at an
early stage, insulin biosynthesis and glucose-stimulated insulin secretion were markedly increased
by liraglutide [35]. In addition, only at an early stage, expression levels of various insulin gene
transcription factors such as MafA and PDX-1 were upregulated by liraglutide. We think that the
increased expression of such factors at an early stage explains the increased insulin biosynthesis and
secretion observed at an early stage. It is likely that the recovery of MafA expression is particularly
important for the recovery of β-cell function and amelioration of glycemic control, since MafA regulates
not only the insulin gene but also various factors related to the glucose-stimulated insulin secretion.
In addition, the expression of GLP-1 receptor was reduced at an advanced stage, which we think
explains the reason why liraglutide did not exert beneficial effects at an advanced stage compared to an
early stage [35]. Taken together, we think that it is very important to start using incretin-based drugs at
an early stage of diabetes to enable incretin-based drugs to fully exert their effect for the protection of
β-cell function.
1.4. Impaired Insulin Signaling in Endothelial Cells Leads to Pancreatic β-Cell Dysfunction
In general, the main insulin target tissues are the liver, skeletal muscle, and adipose tissues,
but there are many kinds of tissues and/or cells in which insulin signaling plays some important role.
In endothelial cells, binding of insulin to insulin receptor on its cell surface activates insulin receptor
substrate (IRS), phosphoinositide 3-kinase (PI3K), and 3-phosphoinositide-dependent protein kinase-1
(PDK1). Such activated insulin signaling leads to augment nitric oxide production in endothelial cells.
Indeed, there have been several reports showing the importance of insulin signaling in endothelial
cells [42–46]. Since it is known that the endothelial cell dysfunction is observed under diabetic
conditions, it is possible that such endothelial dysfunction brings out hypoxia and ischemia in various
tissues through insufficiency of nitric oxide production. In addition, it is known that pancreatic islets
are particularly vulnerable to various stimuli including hypoxia and ischemia, and thereby it is also
possible that endothelial dysfunction leads to exacerbation of pancreatic β-cell function.
Recently, we examined the possible role of PDK1, one of the important molecules in insulin
signaling in vascular endothelial cells, in the maintenance of pancreatic β-cell mass and function. As a
result, vascular endothelial-specific PDK1 knockout mice presented reduced β-cell mass and impaired
β-cell function [47] (Figure 3). These mice also presented reduced blood flow of pancreas and/or islets
and hypoxia of β-cells. In these KO mice, the β-cell mass was significantly reduced and the blood
vessel region in islets was significantly decreased. In addition, in these KO mice, incretin secretion
was augmented after the oral glucose tolerance test but insulin secretion was impaired, suggesting the
impairment of incretin sensitivity in islets of KO mice. Insulin, MafA, PDX-1, GLP-1, and GIP receptor
expression levels were all significantly decreased in islets of KO mice [47]. The microsphere experiment
elucidated the remarkably reduced islet blood flow, and HIF1α and its downstream factor expression
levels were significantly increased in islets of KO mice, indicating that islets of KO mice were in a more
hypoxic state compared to the control mice. Consequently, ER stress-related gene expression levels
were significantly elevated and inflammatory cytokine levels were increased in islets of KO mice [47].
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Figure 3. Association of endothelial cell dysfunction with pancreatic β-cell dysfunction: Involvement of
hypoxia, provoked endoplasmic reticulum (ER) stress, and inflammatory reaction. Ablation of
endothelial PDK1 reduces vascularity in islets, and both pancreatic and islet blood flow are decreased,
which lead to hypoxia in islets and induction of ER stress and inflammation. Therefore, it is likely that
vascular endothelial PDK1 plays an important role in the maintenance of pancreatic β-cell mass and
function by maintaining the vascularity of the pancreas and islets and protecting them from hypoxia,
ER stress, and inflammation.
Taken together, ablation of endothelial PDK1 reduces vascularity in islets, and both pancreatic
and islet blood flow are decreased, which lead to hypoxia in islets and induction of ER stress and
inflammation. Therefore, it is likely that vascular endothelial PDK1 plays an important role in the
maintenance of pancreatic β-cell mass and function by maintaining the vascularity of the pancreas and
islets and protecting them from hypoxia, hypoxia-related ER stress, and inflammation. These are novel
concepts to explain the underlying molecular mechanism for pancreatic β-cell failure and we think
that such findings would be useful when we think about future strategies for type 2 diabetes mellitus
(Figure 3).
2. Incretin Signaling and Atherosclerosis
2.1. Incretin Signaling Plays an Important Role in Arteries
GLP-1 receptor expression is observed not only in the pancreas but also in a variety of tissues
including arteri s such as nd thelial and smooth muscle cells. In endothelial cells, inc etin signaling
is know to improve t e vascular rel x tion response via NOS expression and activity and retard the
devel pment of atherosclero is [48,49]. The i creased xpression of PAI-1 and VCAM-1 and induced
inflammat ry cytokines such as TNF-α under diabetic conditions are suppressed by GLP-1 signaling
in endothelial cells. Taken t gether, it is likely that GLP-1 signaling i blood vessels improves the wall
disorder induce by various factors i cluding hyperglyc mia nd various i flammatory cytokin s.
More r, in vascular mooth muscle cells, GLP-1 re eptor stimulation is known to prevent the
development of atherosclerosis (Figure 4).
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Figure 4. Mechanism of action of incretin and incretin-based agents in vascular cells and reduced
expression of incretin receptor in arteries in a diabetic state. Binding of incretin to the incretin receptor
in vascular cell membrane facilitates nitric oxide production, which leads to the enhancement of
vasodilatory capacity and reduction of atherosclerosis. In a healthy state, the incretin receptor is
abundantly expressed in the vascular cell membrane, but in a diabetic state, incretin receptor expression
is substantially reduced.
In addition, since the GLP-1 receptor is expressed in various cell types, it has not been clearly
elucidated for a long period of time how GLP-1 receptor activators can retard the progression
of atherosclerosis. Very recently, however, the vasoprotective mechanism of the GLP-1 receptor
activator liraglutide was clearly demonstrated at the cellular level after a series of experiments using
global GLP-1 receptor knockout mice, endothelial cell-specific GLP-1 knockout mice, and myeloid
cell-specific GLP-1 receptor knockout mice. As a result, the liraglutide treatment normalized blood
pressure, cardiac hypertrophy, vascular fibrosis, endothelial dysfunction, oxidative stress, and vascular
inflammation in an endothelial GLP-1R-dependent manner, was shown [50]. We think that these recent
findings are unequivocally corroborative evidence that the endothelial GLP-1 receptor expression is
critical for GLP-1 receptor activators to fully exert their effects in arteries.
Atherosclerosis and cardiovascular diseases are typical diabetic complications, which sometimes
fall into serious and lethal situations. Incretin-based therapy using GLP-1 receptor agonists or DPP-IV
inhibitors substantially reduce blood glucose levels without hypoglycemia and/or weight gain,
which leads to prevent diabetic macroangiopathy. In addition, as described above, GLP-1 has direct
protective effects on vascular cells through the GLP-1 receptor. Therefore, it is likely that incretin-based
agents exert beneficial effects against the development of atherosclerosis through both the reduction of
blood glucose levels and their direct effects on vascular cells via the GLP-1 receptor. We should be
aware of these facts and willingly adopt incretin-based therapy in clinical practice, as well.
2.2. Incretin Receptor Expression in Arteries Is Downregulated under Diabetic Conditions
The GLP-1 receptor expression in pancreatic β-cells is reduced under diabetic conditions and
TCF7L2 is known to function as a transcription factor for the GLP-1 receptor at least in β-cells.
We recently showed that the vascular GLP-1 receptor expression was reduced in a diabetic state
as reported in pancreatic β-cells [51] (Figure 4). The GLP-1 receptor and TCF7L2 expression levels
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in endothelial and smooth muscle cells were significantly lower in obese type 2 diabetic mice.
Furthermore, siTCF7L2 decreased the TCF7L2 levels and such reduction of the TCF7L2 level resulted
in the downregulation of GLP-1 receptor expression in cultured vascular endothelial cells. In addition,
when we overexpressed the TCF7L2 level using the TCF7L2 expressing adenovirus, the GLP-1 receptor
expression level was substantially augmented [51,52]. Taken together, the GLP-1 receptor expression
level was significantly lower under diabetic conditions, which was accompanied by the reduction of
the TCF7L2 expression level. These data also indicate that TCF7L2 is a possible regulator of GLP-1
receptor expression in arteries as reported in β-cells. To the best of our knowledge, this is the first
report showing this point, and thus we think such findings would be useful when we create more
efficient therapeutic strategies for type 2 diabetes mellitus.
2.3. Large-Scale Clinical Trials Regarding the Protective Role of Incretin-Based Agents against Atherosclerosis
in Subjects with Type 2 Diabetes Mellitus: SPAED-A and SPIKE Trials
Atherosclerosis is often observed in subjects with type 2 diabetes. In order to predict such
atherosclerosis, carotid intima-media thickness (IMT) is often used as an index of the progression of
atherosclerosis in clinical practice due to its simplicity and reproducibility without being invasive.
It has been reported that the increase of IMT is often observed in diabetic subjects and that there
is a close relationship between carotid IMT and the prevalence and extent of coronary stenosis in
subjects with type 2 diabetes [53–56]. Interestingly, it has been shown recently that incretin-based
agents actually retard the progression of carotid IMT in subjects with type 2 diabetes (Table 1) [57–61].
Table 1. Outline observation in various large-scale clinical trials with incretin-based agents.












Treatment Period 2 years 2 years 3.8 years 2 years 5.4 years 1.3 years

















































IMT: Intima-media thickness; HR: Hazard ratio; CI: Confidence interval; MI: Myocardial infraction.
(1) SPEAD-A trial [57,58]: The aim of this study was to investigate the effects of DPP-IV inhibitor
alogliptin on the progression of carotid atherosclerosis using IMT in subjects with type 2 diabetes.
This prospective, randomized, and multicenter study included 341 subjects without a history of overt
cardiovascular diseases and observed the effects of alogliptin for 2 years. As a result, changes in the
mean common and the right and left maximum IMT of the carotid arteries were significantly greater
after the alogliptin treatment compared to the conventional treatment.
(2) SPIKE trial [59,60]: The aim of this study was to investigate the effects of DPP-IV inhibitor
sitagliptin on the progression of carotid atherosclerosis using IMT in insulin-treated type 2 diabetic
subjects. This prospective, randomized, and multicenter study included 282 insulin-treated subjects
without a history of overt cardiovascular diseases and observed the effects of sitagliptin for 2 years. As a
result, changes in the mean and left maximum IMT of the common carotid arteries were significantly
greater after the sitagliptin treatment compared to the conventional treatment.
There were many basic research reports on the importance of incretin on arteries. To the best of
our knowledge, however, the above-mentioned two large-scale clinical trials, SPEAD-A and SPIKE
trials, were the first large scale clinical reports demonstrating that incretin-based drugs are actually
useful to prevent the development of atherosclerosis in clinical practice. These data clearly indicate that
incretin-based agents function to retard the progression of carotid atherosclerosis in subjects with type
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2 diabetes without a history of overt cardiovascular disease regardless of the use of insulin therapy.
Since it is likely that such findings would lead to the prevention of cardiovascular events in the long
run, we should bear in mind in clinical practice that incretin-based agents possess anti-atherosclerotic
effects, in addition to original anti-diabetic effects. Thereby, we should willingly adopt incretin-based
therapy in clinical practice.
2.4. Large-Scale Clinical Trials Regarding the Protective Role of Incretin-Based Agents against Cardiovascular
Events in Subjects with Type 2 Diabetes Mellitus: LEADER, SUSTAIN-6, REWIND, PIONEER 6 Trials
While atherosclerosis and subsequent cardiovascular events sometimes fall into serious and lethal
situations, it has been reported recently that the administration of GLP-1 receptor activator leads to
the reduction of cardiovascular events and cardiovascular-related death (Table 1) [57–64], in addition
to atherosclerosis as described above. The importance of incretin-based agents in forestalling the
progression of atherosclerosis has been reported in succession very recently, and thus the role of the
GLP-1 receptor activator in vascular cells has been capturing the spotlight.
(1) LEADER trial [61,62]: This prospective, randomized, and multicenter study included 9340 subjects
and allocated to either the once-daily injection liraglutide or the control group. The median follow-up
period was 3.8 years. The primary composite outcome was the first occurrence of cardiovascular death,
nonfatal myocardial infarction, or nonfatal stroke. As a result, the primary outcome occurred in significantly
fewer patients in the liraglutide group (13.0%) compared to the placebo group (14.9%) (hazard ratio (HR):
0.87, 95% confidence interval (CI): 0.78–0.97). Moreover, fewer subjects died from cardiovascular causes in
the liraglutide group (4.7%) compared to the placebo (6.0%) (HR: 0.78, CI: 0.66–0.93). The rate of death
from any cause was lower in the liraglutide group (8.2%) compared to the placebo (9.6%) (HR: 0.85,
CI: 0.74–0.97). The rates of nonfatal myocardial infarction, nonfatal stroke, and hospitalization for heart
failure were relatively lower in the liraglutide group. The rate of the first occurrence of death from
cardiovascular causes, nonfatal myocardial infarction, and nonfatal stroke were lower in the liraglutide
group compared to the placebo. Taken together, the once-daily injection liraglutide is expected to prevent
major adverse cardiovascular events.
(2) SUSTAIN-6 trial [63,64]: This study included 3297 subjects with type 2 diabetes, randomly
allocated to either the once-weekly semaglutide or the placebo and was followed up for 2 years.
The primary composite outcome was the first occurrence of cardiovascular death, nonfatal myocardial
infarction, or nonfatal stroke. As a result, the primary outcome occurred in 6.6% subjects in the
semaglutide group and in 8.9% subjects in the placebo group (HR: 0.74, CI: 0.58–0.95). HR (CI) in
nonfatal myocardial infarction was 0.74 (0.51–1.08), and that in nonfatal stroke was 0.61 (0.38–0.99).
In conclusion, the once-weekly injection semaglutide is also expected to prevent major adverse
cardiovascular events.
(3) REWIND trial [65,66]: The aim of this study was to assess the effect of the once-weekly injection
dulaglutide on major adverse cardiovascular events in subjects with type 2 diabetes with and without
previous cardiovascular disease and a wide range of glycemic control. A total of 9901 participants who
had either a previous cardiovascular event or cardiovascular risk factors were randomly assigned to
receive the dulaglutide or placebo. The primary outcome was the first occurrence of the composite
endpoint of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke. This study
included 9901 participants, and a median follow up period was 5.4 years. As a result, HR (CI) in the
primary composite outcome was 0.88 (0.79–0.99), and that in the all cause death was 0.90 (0.80–1.01).
Taken together, the once-weekly injection dulaglutide is also expected to prevent major adverse
cardiovascular events.
(4) PIONEER 6 trial [67,68]: The aim of this study was to assess the effect of the once-weekly
oral semaglutide on major adverse cardiovascular events. A total of 3183 patients were randomly
assigned to receive the oral semaglutide or placebo. The primary outcome was the first occurrence of a
major adverse cardiovascular event (cardiovascular death, nonfatal myocardial infarction, or nonfatal
stroke). As a result, the median time in the trial was 1.3 years. The HR in major adverse cardiovascular
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events was 0.79 (CI: 0.57–1.11). The other HRs were as follows: Death from cardiovascular causes
(HR: 0.49, CI: 0.27–0.92) and all-cause death (HR: 0.51, CI: 0.31–0.84). In conclusion, the once-weekly
oral semaglutide is also expected to prevent major adverse cardiovascular events.
The above-mentioned four large-scale clinical trials strongly corroborate the hypothesis that
incretin-based agents exert a protective role against cardiovascular events and/or cardiovascular-related
death in subjects with type 2 diabetes. Therefore, in clinical practice, we should willingly use
incretin-based agents in subjects with type 2 diabetes, especially in subjects with a large risk of
atherosclerosis and/or cardiovascular events.
3. Conclusions
In this review article, we featured notable underlying mechanisms for pancreaticβ-cell dysfunction
found in diabetes and the development of atherosclerosis, the first stage of diabetic macroangiopathy
leading to cardiovascular events, especially focusing on the pleiotropic role of incretin and insulin
signaling in various situations.
Our ideas at present on the pancreatic β-cell dysfunction are as follows: First, in a diabetic state,
the expression levels of insulin gene transcription factors (MafA and PDX-1) are downregulated,
which we think substantially explains the molecular mechanism for β-cell glucose toxicity. In clinical
practice, it is very important to alleviate such β-cell glucose toxicity in order to forestall the exacerbation
of diabetes. Second, incretin signaling plays very important roles in pancreatic β-cells, but incretin
sensitivity in β-cells is weakened under diabetic conditions, at least in part due to the downregulation
of GLP-1 receptor expression, which we think may be associated with an aggravation of the β-cell
function. The data also suggest that it would be better to use incretin-related drugs at an early stage
of diabetes, and indeed incretin-related drugs exert more protective effects on β-cells at an early
stage. Third, endothelial cell dysfunction and subsequent hypoxia or ischemia in β-cells are also likely
associated with the β-cell dysfunction found in diabetes. Indeed, after ablation of insulin signaling in
endothelial cells, the β-cell function and mass are markedly reduced, which is also accompanied by
reduced expression of insulin gene transcription factors and incretin receptors.
Our present ideas on atherosclerosis are as follows: First, incretin signaling plays very important
anti-atherosclerotic roles in arteries, but incretin sensitivity in arteries is weakened, at least partially
due to the downregulation of GLP-1 receptor expression, which we think may lead to the development
of atherosclerosis. Second, a series of large-scale clinical trials have shown that various incretin-related
drugs have beneficial effects against atherosclerosis and cardiovascular events. These data strengthen
the importance of incretin signaling in arteries of humans, as well as rodents. Taken together,
incretin signaling plays a crucial role in various tissues, and incretin-related drugs are promising from
clinical points of view, as well as a basic research area.
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